Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
RESEARCH TOOLSreports
DNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.26 - $64.40
Previous CloseN/A
Volume618.97K
Average Volume (3M)1.70M
Market Cap
$791.48M
Enterprise Value$252.33M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.03
Next Earnings
Feb 25, 2025EPS Estimate
-1.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.90
Shares Outstanding45,199,330
10 Day Avg. Volume2,240,847
30 Day Avg. Volume1,699,362
Standard Deviation0.23
R-Squared0.08
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.34
Price to Cash Flow (P/CF)-1.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.28
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$16.00Price Target Upside39.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
RestructuringRestructuring efforts are approximately six months ahead of schedule, with potential for further cost savings on top of $200 million run rate by mid-2025.
RevenueStrong Q3 driven by $45 million in released deferred revenues from terminated contract with Motif.
Bears Say
GrowthCash/profitability prioritization could weigh on NTM top-line growth.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $5.26 and its highest was $64.40 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Ginkgo Bioworks Holdings’s market cap is $791.48M.
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Feb 25, 2025 which is in 3 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Nov 12, 2024. The company reported -$1.08 earnings per share for the quarter, beating the consensus estimate of -$2.728 by $1.648.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -1.5.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 45,199,330 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$1.08 in its last earnings report, beating expectations of -$2.728. Following the earnings report the stock price went up 2.503%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Currently, no hedge funds are holding shares in DNA
---
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (39.98% Upside)
$16.00 (39.98% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 55%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-79.14%
12-Months-Change
Fundamentals
Return on Equity
-81.61%
Trailing 12-Months
Asset Growth
-26.92%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc. is a biotechnology company that specializes in using synthetic biology to engineer microorganisms for a variety of applications in different industries. The company operates in sectors such as pharmaceuticals, agriculture, food, and industrial chemicals, providing custom-designed organisms that can produce specific biochemical products. Ginkgo Bioworks aims to leverage its platform to enable the scalable and cost-effective production of biobased products, thus transforming traditional manufacturing processes.
---
DNA Company Deck
---
DNA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Ginkgo Bioworks is making strong progress in cost management and achieving technical milestones with major customers, despite facing challenges in revenue from cell engineering and biosecurity. The company maintains a robust cash position and is ahead of schedule in cost-cutting targets. However, declines in certain revenue streams and the impact of one-off costs on cash burn present challenges. Overall, the company is on a positive trajectory towards breakeven.Read More>---
DNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
---
DNA Stock 12 Month Forecast
Average Price Target
$16.00
▲(39.98% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Twist Bioscience
―
Best Analysts Covering DNA
1 Year
1 Year Success Rate
5/6 ratings generated profit
1 Year Average Return
+45.20%
reiterated a sell rating 6 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +45.20% per trade.
---